Clinical trial NCT06261060: Low-Dose Sirolimus to Increase Hematopoietic Function in Patients With RUNX1 Familial Platelet Disorder
Official title: Low-Dose Sirolimus to Increase Hematopoietic Function in Patients With RUNX1 Familial Platelet Disorder
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE2
Conditions: Familial Platelet Disorder
Hematopoietic
Lead sponsor: M.D. Anderson Cancer Center
Sponsor class: OTHER
First posted: 2024-02-15
Enrollment: 6
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: To learn about the safety and effects of low-dose sirolimus in participants with RUNX1-FPD.

Detailed description: Primary Objective:

• Evaluate the safety and tolerability of low-dose sirolimus in participants with RUNX1 familial platelet disorder (RUNX1-FPD)

Secondary Objectives:

* Evaluate increases in platelet counts during and after treatment with low-dose sirolimus
* Evaluate changes in somatic mutation variant allele frequency (VAF)
* Monitor the rate of somatic mutation acquisition (ie, mutation burden)
* Assess change in platelet aggregation score
* Measure the change from baseline in bleeding score (ISTH-BAT)
* Evaluate change in mTORC1 downstream signaling (pS6/EBP)

Exploratory Objectives:

* Measure rescue of elevated cytokine profiles
* Evaluate reversal of myeloid skewing using flow cytometry
* Determine changes in bone marrow (eg, megakaryocytic atypia and cellularity)
* Assess changes in patient-reported outcomes measures (eg, EORTC and PRO-CTCAE)
* Describe the pharmacokinetics of sirolimus in patients with RUNX1-FPD
* Determine the correlation between sirolimus trough levels and each endpoint

Eligibility criteria: Inclusion Criteria:

* Participants has provided signed, informed consent before initiation of any study specific procedures
* Aged ≥18 years at the time of signing the informed consent
* Confirmed P/LP germline RUNX1 variant per ClinGen Myeloid Malignancy Variant Curation Expert Panel (MM-VCEP) RUNX1-specific variant curation rules80
* Participants must be willing to provide bone marrow sample at time of screening and at the end of treatment with sirolimus
* Platelet count of ≥50,000/µL
* Adequate renal function: estimated glomerular filtration rate based on Modification of Diet in Renal Disease (MDRD) calculation, \>30 mL/min/1.73m2
* Adequate hepatic function: aspartate aminotransferase (AST) and alanine aminotransferase (ALT) \<3 × upper limit of normal (ULN) and total bilirubin \<1.5 × ULN
* Adequate cardiac function: left ventricular ejection fraction \>50%

Exclusion Criteria:

* Known allergy to sirolimus
* History of lymphoma or other hematologic malignancies
* Uncontrolled bleeding
* Any prior diagnosis of myelodysplastic syndrome or other hematologic malignancy using International Working Group criteria
* Prior treatment with sirolimus or a rapalog, mTOR inhibitor, or B-cell-depleting therapy within 28 days before study day 1
* Treatment with strong inhibitors of cytochrome P450 3A4 (CYP3A4; eg, ketoconazole, voriconazole, itraconazole, erythromycin, telithromycin, and clarithromycin), strong inducers of CYP3A4 (eg, rifampin and rifabutin), other drugs that could increase sirolimus blood concentrations (eg, bromocriptine, cimetidine, cisapride, clotrimazole, danazol, diltiazem, fluconazole, letermovir, protease inhibitors \[eg, ritonavir, indinavir, boceprevir, and telaprevir\], metoclopramide, nicardipine, troleandomycin, and verapamil), other drugs that could decrease sirolimus blood concentrations (eg, carbamazepine, phenobarbital, phenytoin, rifapentine, St. John's Wort \[Hypericum perforatum\]), or drugs with blood concentrations that could increase (eg, verapamil) within 7 days before study day 1
* Use of cannabidiol, which can increase blood levels of sirolimus, within 7 days before study day 1
* Myocardial infarction within 6 months before study day 1, congestive heart failure (New York Heart Association \> class II)
* Total cholesterol \>300 mg/dL or triglyceride \>400 mg/dL
* Arterial thrombosis (eg, stroke or transient ischemic attack) within 6 months before study day 1
* Infection requiring intravenous anti-infective treatment within 1 week of study day 1
* Live vaccines (eg, measles, mumps, rubella, oral polio, BCG, yellow fever, varicella, and TY21a typhoid) within 28 days before study day 1
* Known diagnosis of chronic viral infection (eg, hepatitis B or C or HIV, and Epstein-Barr) or tuberculosis
* Women who are pregnant, may become pregnant, or who are breastfeeding

Primary outcomes:
measure: Safety and adverse events (AEs)
timeFrame: Through study completion; an average of 1 year
Secondary outcomes:
Other outcomes:
Locations:
city: Houston
country: United States
facility: MD Anderson Cancer Center
state: Texas
Study officials:
affiliation: M.D. Anderson Cancer Center
name: Courtney DiNardo, MD
role: PRINCIPAL_INVESTIGATOR
References: